Details for Patent: 9,951,043
Which drugs does patent 9,951,043 protect, and when does it expire?
Patent 9,951,043 protects SUNLENCA, YEZTUGO, BIXLENVO, and BIXLENVO SUNLENCA STARTER PACK (COPACKAGED), and is included in six NDAs.
This patent has sixty-six patent family members in thirty-six countries.
Summary for Patent: 9,951,043
| Title: | Therapeutic compounds |
| Abstract: | Compounds of formula (I) or salts thereof are disclosed. Also disclosed are pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus. |
| Inventor(s): | Gediminas Brizgys, Eda Canales, Chien-Hung Chou, Michael Graupe, Randall L. Halcomb, Yunfeng Eric Hu, Scott E. Lazerwith, John O. Link, Qi Liu, Yafan Lu, Roland D. SAITO, Scott D. Schroeder, John R. SOMOZA, Winston C. Tse, Jennifer R. Zhang |
| Assignee: | Gilead Sciences Inc |
| Application Number: | US14/771,779 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 9,951,043
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | SUNLENCA | lenacapavir sodium | SOLUTION;SUBCUTANEOUS | 215973-001 | Dec 22, 2022 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | IN COMBINATION WITH OTHER ANTIRETROVIRAL(S), FOR THE TREATMENT OF HIV-1 INFECTION IN HEAVILY-TREATMENT EXPERIENCED ADULTS WITH MULTIDRUG RESISTANT HIV-1 INFECTION | ⤷ Start Trial | ||
| Gilead Sciences Inc | YEZTUGO | lenacapavir sodium | SOLUTION;SUBCUTANEOUS | 220018-001 | Jun 18, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | FOR PRE-EXPOSURE PROPHYLAXIS TO REDUCE THE RISK OF SEXUALLY ACQUIRED HIV-1 IN ADULTS AND ADOLESCENTS WEIGHING AT LEAST 35 KG WHO ARE AT RISK FOR HIV-1 ACQUISITION | ⤷ Start Trial | ||
| Gilead Sciences Inc | BIXLENVO | bictegravir sodium; lenacapavir sodium | TABLET;ORAL | 221104-001 | Aug 27, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | TREATMENT OF HIV-1 IN ADULTS TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IN THOSE WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN | ⤷ Start Trial | ||
| Gilead Sciences Inc | BIXLENVO SUNLENCA STARTER PACK (COPACKAGED) | bictegravir sodium, lenacapavir sodium; lenacapavir sodium | TABLET;ORAL | 221443-001 | Aug 27, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | TREATMENT OF HIV-1 IN ADULTS TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IN THOSE WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN | ⤷ Start Trial | ||
| Gilead Sciences Inc | SUNLENCA | lenacapavir sodium | TABLET;ORAL | 215974-001 | Dec 22, 2022 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | IN COMBINATION WITH OTHER ANTIRETROVIRAL(S), FOR THE TREATMENT OF HIV-1 INFECTION IN HEAVILY-TREATMENT EXPERIENCED ADULTS WITH MULTIDRUG RESISTANT HIV-1 INFECTION | ⤷ Start Trial | ||
| Gilead Sciences Inc | SUNLENCA | lenacapavir sodium | TABLET;ORAL | 215974-001 | Dec 22, 2022 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | TREATMENT OF HIV-1 IN ADULTS TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IN THOSE WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN | ⤷ Start Trial | ||
| Gilead Sciences Inc | YEZTUGO | lenacapavir sodium | TABLET;ORAL | 220020-001 | Jun 18, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | FOR PRE-EXPOSURE PROPHYLAXIS TO REDUCE THE RISK OF SEXUALLY ACQUIRED HIV-1 IN ADULTS AND ADOLESCENTS WEIGHING AT LEAST 35 KG WHO ARE AT RISK FOR HIV-1 ACQUISITION | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,951,043
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 094990 | ⤷ Start Trial | |||
| Argentina | 118856 | ⤷ Start Trial | |||
| Australia | 2014223973 | ⤷ Start Trial | |||
| Australia | 2016262671 | ⤷ Start Trial | |||
| Australia | 2018247348 | ⤷ Start Trial | |||
| Brazil | 112015021027 | ⤷ Start Trial | |||
| Canada | 2901502 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
